Modified Delphi consensus on the use of cladribine tablets in relapsing-remitting multiple sclerosis in North-West Africa
Authors:
- 14 July 2026
- journal article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 113, 107393
Abstract
No abstract availableKeywords
Funding Information
- Merck
This publication has 27 references indexed in Scilit:
- Efficacy and safety of Cladribine as a therapeutic option in multiple sclerosis patients over 50 years of age: A real-world studyJournal of the Neurological Sciences, 2025
- Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE studyMultiple Sclerosis and Related Disorders, 2023
- Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in LebanonMultiple Sclerosis and Related Disorders, 2022
- Expert-Agreed Practical Recommendations on the Use of CladribineNeurology and Therapy, 2022
- Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinionJournal of Neurology, 2022
- Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s ReviewNeurology and Therapy, 2022
- Long-term safety data from the cladribine tablets clinical development program in multiple sclerosisMultiple Sclerosis and Related Disorders, 2020
- Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical TrialsJAMA Neurology, 2020
- Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple SclerosisJAMA Neurology, 2019
- Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysisMultiple Sclerosis and Related Disorders, 2019